Skip to main content
PZ Cormay S.A. logo

PZ Cormay S.A. — Investor Relations & Filings

Ticker · CRM ISIN · PLCMRAY00029 LEI · 2594006HZJ8OSNK56U87 WAR Manufacturing
Open in API
Filings indexed 692 across all filing types
Latest filing 2018-01-29 Report Publication Anno…
Country PL Poland
Listing WAR CRM

About PZ Cormay S.A.

https://cormaydiagnostics.com/

PZ Cormay S.A. is a manufacturer and distributor of in-vitro diagnostic (IVD) solutions for medical laboratories and clinics. The company develops, produces, and sells a comprehensive portfolio of diagnostic reagents, laboratory analyzers, and quality control systems. Its offerings cater to key diagnostic areas, including clinical chemistry, hematology, and immunoassay. Key product lines feature the Accent series of chemistry analyzers, the Auryx immunoassay system, and the Mythic family of hematology analyzers. The company integrates its extensive experience in reagent manufacturing with advanced Swiss hematology technology to provide reliable, high-performance, and cost-effective diagnostic tools to a global network of distributors and healthcare professionals.

Recent filings

Filing Released Lang Actions
Terminy przekazywania raportów okresowych w 2018 roku - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text explicitly lists the dates when various periodic reports (quarterly, semi-annual, and annual reports for 2017 and 2018) will be published by PZ CORMAY S.A. It details the schedule for releasing consolidated quarterly reports, the semi-annual report, and the annual reports. Since the document's sole purpose is to announce the future publication schedule of these financial reports, it fits the definition of a Report Publication Announcement (RPA). The document length (1645 chars) is short, supporting the 'announcement' classification over the actual report classification (like 10-K or IR).
2018-01-29 Polish
Aktualizacja oceny ryzyka zwrotu dotacji - Content (PL)
Legal Proceedings Report Classification · 95% confidence The document discusses changes in the risk assessment related to the repayment of grants (dotacji) tied to specific R&D projects (Umowa Equisse, Umowa Blue Box, Umowa Hermes Senior). It details interactions with financing institutions (RIF, PARP) regarding requests to change performance indicators deadlines and the potential obligation to return previously received funding if targets are missed. This content relates to the financial status, regulatory compliance regarding grants, and potential liabilities. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It is a specific disclosure about financial risk and compliance related to government funding, which fits best under 'Legal Proceedings Report' (LTR) if it involves regulatory/legal disputes over funding, or potentially 'Capital/Financing Update' (CAP) due to the nature of the funds, but the focus is on the *risk of repayment* and regulatory compliance concerning grants. Given the context of reporting on potential liabilities arising from non-compliance with grant agreements, 'Legal Proceedings Report' (LTR) is a plausible fit, although 'Regulatory Filings' (RNS) is often used for specific, non-standard disclosures in Polish markets. However, since it details specific legal/contractual risks and interactions with regulatory bodies concerning financial obligations, and it is not a standard financial report, LTR is a strong candidate. If we consider the nature of the disclosure as a significant event impacting financial obligations due to regulatory/contractual non-adherence, LTR is appropriate. If it were a general announcement of a regulatory filing, RNS would apply. Since it contains the substance of the issue, LTR is chosen over RNS.
2018-01-12 Polish
Status projektów Equisse, Hermes Senior – aktualizacja informacji - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a formal communication from the Management Board ("Zarząd") of PZ Cormay S.A. It provides a detailed update on the progress of two key development projects: 'Equisse' and 'Hermes Senior'. It references previous periodic reports (quarterly report for Q3 2017) and details specific operational milestones, regulatory filings (URPL, SwissMedic registration), testing phases ('friendly users'), and future timelines (Q1 2018, Q2 2018, H1 2019). This content—a comprehensive update on business operations, development progress, and outlook, often referencing financial periods—is characteristic of a Management Discussion and Analysis (MDA) section or a detailed operational report update, rather than just a brief earnings release (ER) or a general regulatory filing (RNS). Since it focuses heavily on management's explanation of project status and outlook, MDA is the most appropriate classification.
2018-01-08 Polish
Podpisanie umowy o dofinansowanie Projektu: „Stworzenie CBR PZ Cormay S.A.” - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text describes the signing of a financing agreement (Umowa o dofinansowanie) by PZ Cormay S.A. for a specific R&D project, detailing the total cost, eligible expenses, maximum funding amount from the European Regional Development Fund, and the commitment period. This announcement concerns the company securing funding and making capital structure commitments related to investment/financing activities, rather than being a standard regulatory report (like 10-K or IR) or a general regulatory filing (RNS). The content directly relates to fundraising, financing activities, and capital structure changes, fitting the definition of 'Capital/Financing Update'.
2017-12-15 Polish
Uchwała KDPW w sprawie asymilacji akcji serii L - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text, written in Polish, discusses an action taken by the Management Board of KDPW (National Securities Depository) regarding the assimilation (merger/reclassification) of a large number of company shares (13,481,054 Series L shares into existing shares), resulting in a new total share count (77,205,008). This action directly relates to the company's capital structure and the identification codes of its securities. This falls under the category of changes in capital structure or share issuance/reclassification. Given the options, 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as it describes a fundamental change in the composition or identification of the outstanding shares. It is not a general earnings release (ER), a dividend notice (DIV), or a director's dealing (DIRS). The document is a formal regulatory announcement regarding a capital structure event.
2017-12-06 Polish
Uchwała GPW w sprawie dopuszczenia i wprowadzenia do obrotu giełdowego akcji serii L - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from the Management Board of PZ CORMAY S.A. regarding a resolution from the Warsaw Stock Exchange (GPW) concerning the admission of a specific series of shares (Series L) to trading on the parallel market, effective December 7, 2017. This announcement details a change related to the listing and trading of the company's securities, which falls under general regulatory disclosures. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a specific shareholder vote result (DVA). It is a specific regulatory notification concerning the listing status of shares. While it relates to capital structure, it is primarily an official notice about market operations. Given the nature of the announcement (official notice regarding stock exchange admission/trading rules) and the lack of a more specific category like Share Issue/Capital Change (SHA) which usually implies issuance or buybacks, this fits best under the general regulatory disclosure category, RNS, as it is a mandatory, specific regulatory filing that doesn't fit the other defined categories perfectly, although it is highly specific. However, upon re-evaluation against the definitions, the content is a direct notification about the admission of shares to trading, which is a significant event impacting the capital structure and trading mechanism. Since the document is short (1381 chars) and is a direct announcement of an official regulatory action (GPW resolution), it functions as a mandatory regulatory filing. RNS (Regulatory Filings) is the appropriate fallback for such specific, non-standard disclosures not covered by ER, 10-K, or CAP (which usually implies fundraising/financing activities rather than listing mechanics). Given the context of Polish regulatory filings, this type of announcement regarding listing admission is typically categorized as a general regulatory filing.
2017-12-01 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.